Wednesday, May 7, 2014

VistaGen Therapeutics, Inc. (VSTA) Approved to Expand Intellectual Property Portfolio for Stem Cell Technology Platform

VistaGen Therapeutics is a biotechnology company whose focus is on applying pluripotent stem cell technology for drug rescue and regenerative medicine. The company, which is based out of San Francisco, has been in the business of human pluripotent stem cell (hPSC) technology for over 16 years.

Human pluripotent cells are the building blocks of all cells of the human body. VistaGen believes that controlling the differentiation of these kinds of cells can make stronger and better cells that will benefit drug rescue and regenerative medicine initiatives.

VistaGen’s approach to drug rescue and regenerative medicine is unique because of the products the company chooses to work with. It selects drug candidates that have been abandoned by other biotechnology and pharmaceutical companies and uses its technology to generate new chemical variants of them.

These candidates are perfectly usable, but were abandoned before the market approval stage because of concerns related to their effect on patients’ hearts and livers.

VistaGen is confident it can rework these abandoned candidates into something usable, with an end goal of creating a pipeline of Drug Rescue Variants™. These Variants can then be sold to biotechnology and pharmaceutical companies who can then develop them, get them approved, and then sell them commercially.

VistaGen shared exciting news in April 2014 when it found out that it had received a Notice of Allowance from the United States Patent and Trademark Office regarding an application for a patent to expand one of its technology platforms, LiverSafe 3D™. The patent will expand VistaGen’s intellectual property portfolio to stem cell culture systems that produce cells for the liver, lung, pancreas, and thyroid. The company believes that LiverSafe 3D™ will benefit from this expanded intellectual platform.

For more information, please visit www.vistagen.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

 VistaGen Therapeutics, Inc. (VSTA) Approved to Expand Intellectual Property Portfolio for Stem Cell Technology Platform

VistaGen Therapeutics is a biotechnology company whose focus is on applying pluripotent stem cell technology for drug rescue and regenerative medicine. The company, which is based out of San Francisco, has been in the business of human pluripotent stem cell (hPSC) technology for over 16 years.

Human pluripotent cells are the building blocks of all cells of the human body. VistaGen believes that controlling the differentiation of these kinds of cells can make stronger and better cells that will benefit drug rescue and regenerative medicine initiatives.

VistaGen’s approach to drug rescue and regenerative medicine is unique because of the products the company chooses to work with. It selects drug candidates that have been abandoned by other biotechnology and pharmaceutical companies and uses its technology to generate new chemical variants of them.

These candidates are perfectly usable, but were abandoned before the market approval stage because of concerns related to their effect on patients’ hearts and livers.

VistaGen is confident it can rework these abandoned candidates into something usable, with an end goal of creating a pipeline of Drug Rescue Variants™. These Variants can then be sold to biotechnology and pharmaceutical companies who can then develop them, get them approved, and then sell them commercially.

VistaGen shared exciting news in April 2014 when it found out that it had received a Notice of Allowance from the United States Patent and Trademark Office regarding an application for a patent to expand one of its technology platforms, LiverSafe 3D™. The patent will expand VistaGen’s intellectual property portfolio to stem cell culture systems that produce cells for the liver, lung, pancreas, and thyroid. The company believes that LiverSafe 3D™ will benefit from this expanded intellectual platform.

For more information, please visit www.vistagen.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: